Skip to search formSkip to main contentSkip to account menu

CGS 8515

Known as: CGS-8515 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Effects of 5-Lipoxygenase Inhibitors on Guinea Pig Trachea in Ovalbumin-Induced Experimental Asthma
Objective: The 5-lipoxygenase products, especially sulfidopeptide leukotrienes take an important role in the pathogenesis of… 
1995
1995
Effects of platelet-activating factor antagonists WEB 2086 and BN 50730 on digoxin-induced arrhythmias.
Effects of platelet-activating receptor antagonists WEB 2086 (1.0-30.0 mg.kg-1 intravenously) and BN 50730 (10.0 mg.kg-1… 
1993
1993
CGS 8515 and indomethacin attenuate cytokine-induced cardiopulmonary dysfunction in pigs.
We evaluated the effect of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 alpha (IL-1 alpha) on pig cardiopulmonary… 
1990
1990
Pharmacokinetic Screening of o-Naphthoquinone 5-Lipoxygenase Inhibitors
The o-naphthoquinone derivative, CGS 8515 (I), is a potent inhibitor (IC50, 0.1 µM) of 5-lipoxygenase, but its therapeutic… 
1989
1989
Characterization of CGS 8515 as a selective 5-lipoxygenase (5-LO) inhibitor.
1. CGS 8515 selectively inhibited 5-LO (IC50 = 0.1 microM) with negligible effect on CO, 12-LO, 15-LO and TxS at concentrations… 
1988
1988
Inhibition of leukotriene release in anaphylactic guinea‐pig hearts by a 5‐lipoxygenase inhibitor, CGS 8515
1 Ovalbumen (100μg)‐induced coronary vasoconstriction and decrease in cardiac developed tension were studied in isolated perfused… 
1988
1988
Modulation of arachidonic acid metabolites and vulnerability to ventricular fibrillation during myocardial ischemia in the cat.
1988
1988
Characterization of CGS 8515 as a selective 5-lipoxygenase inhibitor using in vitro and in vivo models.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)